Accuray Incorporated Stock News

Accuray Incorporated (ARAY) CEO Joshua Levine on Q2 2022 Earnings Call Transcript

Accuray press release (ARAY): FQ2 GAAP EPS of $0.00 in-line.Revenue of $116.28M (+19.3% Y/Y) beats by $13.35M.Shares +10.57%.Gross orders of $85.4 million, an increase of 13…

Accuray (ARAY) delivered earnings and revenue surprises of -100% and 10.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Accuray (NASDAQ:ARAY) is scheduled to announce Q2 earnings results on Wednesday, January 26th, after market close.The consensus EPS Estimate is $0.01 (-80.0% Y/Y) and the consensus

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SUNNYVALE, Calif., Jan. 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2022, ended December 31, 2021, after the mark

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

New York, Dec. 17, 2021 (GLOBE NEWSWIRE) -- According to the new market research report " Radiotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (External-Beam Radiation Therapy, Internal Radiation Therapy, and Systemic Radiotherapy/Radiopharmaceuticals), Product (External Beam Radiotherapy Products, Internal Radiotherapy Products, Radiotherapy Software, and Others), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Liver Cancer, Thyroid Cancer, Brain Cancer, Cervical Cancer, Spine Cancer, and Others), and End User (Hospitals, Radiation Therapy Centers, and Specialty Clinics), and Geography", published by The Insight Partners , the global radiotherapy market was valued at US$ 6,474.78 million in 2020 and it is projected to reach US$ 10,170.80 million by 2028; it is expected to grow at a CAGR of 5.9% from 2021 to 2028. Get Exclusive Sample Pages of Radiotherapy Market Size - COVID-19 Impact and Global Analysis with Strategic Insights: https://www.theinsightpartners.com/sample/TIPMD00002668/ Radiotherapy Market: Competition Landscape and Key Developments Siemens Healthineers AG, Accuray Incorporated, Sumitomo Heavy Industries, Ltd., Elekta AB, Hitachi, Ltd., Koninklijke Philips N.V., Brainlab AG, PROTOM INTERNATIONAL, Varian Medical Systems, Inc., Maastro, and Mevion Medical Systems are among the key companies operating in the radiotherapy market.

Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray